On one hand, as previously mentioned, our research findings provide translational relevance for MTC, as it would support the rationale for combination trials of RET kinase inhibitors with immune checkpoint inhibitors for RET-mutant MTCs. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.